JUL 10, 2018 04:10 PM PDT

Reducing Cholesterol with Gene Editing

WRITTEN BY: Carmen Leitch

Scientists know that there is a link between a protein called PCSK9 and cholesterol; when the protein is not active, cholesterol levels go down. Therapies that aim to use this relationship to the patient’s advantage have focused on inhibiting drugs. A new study has used gene editing to inactivate the protein in rhesus macaque monkeys; the researchers were able to successfully lower cholesterol levels in those monkeys. This work, reported in Nature Biotechnology, may open up new approaches for treating patients with heart disease that cannot take PCSK9 inhibitors, which are often used to control high cholesterol.

Pictured is a cholesterol-filled atherosclerotic coronary artery from a human body. /Credit: Courtesy: University of Pennsylvania School of Medicine

In healthy people, PCSK9 can stop receptors from taking up excess bad cholesterol, called LDL, in the liver. It’s been found that drugs that inhibit the PCSK9 protein can lower cholesterol in people. However, some people with a severe type of cardiovascular disease called hypercholesterolemia cannot take these drugs. This research has shown that gene editing may be helpful for these cases.

"Most often these patients are treated with repeated injections of an antibody to PCSK9," noted first author Lili Wang, Ph.D., a research associate professor of Medicine. "But, our study shows that with successful genome editing, patients who cannot tolerate inhibitor drugs might no longer need this type of repeat treatment."

A Durham, NC biotech called Precision Biosciences coauthored this work. They created an enzyme that could recognize PCSK9, and inactivate it. The enzyme, called a meganuclease, was used along with a molecular tool called an adeno-associated virus (AAV) to target the therapeutics to the liver of the primate research model.

In animals that were exposed to middle- and high-dose AAV vectors, the levels of PCSK9 were reduced from 30 to 60 percent. The AAV vector that was used in this study has been shown in clinical trials to be safe and effective.

"Our initial work with several delivery and editing approaches produced the most impressive data in non-human primates when we paired AAV for delivery with the engineered meganuclease for editing," said senior author James M. Wilson, MD, Ph.D., a professor of Medicine and Pediatrics and director of the Gene Therapy Program at Penn. "We leveraged our 30-plus years of experience in gene therapy to progress the translational science of in vivo genome editing, and in doing so, reinforced the importance of early studies in nonhuman primates to assess safety and efficacy."

The researchers want to be sure that any gene edits they make in patients are limited to the PCSK9 gene. They also need to monitor for effects on the immune system. This work will hopefully help those suffering not only from hypercholesterolemia but a variety of metabolic diseases caused by gene mutations, and which affect the liver.

 

Sources: AAAS/Eurekalert! Via Penn Medicine News, Nature Biotechnology

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 25, 2018
Microbiology
NOV 25, 2018
Researchers Learn How Hantavirus Infects Cells
First identified in 1993, hantavirus infections can cause dangerous and potentially deadly respiratory infections....
DEC 03, 2018
Genetics & Genomics
DEC 03, 2018
Reducing the Potential for Negative Side Effects in CRISPR
CRISPR-Cas9 is an amazing gene-editing tool, but there are some drawbacks. This work aims to fix that....
DEC 05, 2018
Videos
DEC 05, 2018
Promising Results From Early Trials of Gene Therapy for Sickle Cell Anemia
More than 90,000 Americans and millions of people around the world have SCA....
DEC 17, 2018
Health & Medicine
DEC 17, 2018
A Migraine Associated Specific Mutation Increases Neuronal Excitability
One subtype of K2P channel expressed in sensory neurons, TRESK has been reported to play a role in MA in its truncated from TRESK-MT....
DEC 22, 2018
Videos
DEC 22, 2018
Using Genomics to Fight Cancer
Genetic sequencing can help clinicians decide on the best treatment for individual patients....
JAN 20, 2019
Genetics & Genomics
JAN 20, 2019
Identifying Genetic Regions That Influence Lifespan
It may one day be possible to predict how long a person will live by looking at a few regions of a person's genome....
Loading Comments...